Author:
Zwierzina H, ,Suciu S,Loeffler-Ragg J,Neuwirtova R,Fenaux P,Beksac M,Harousseau J,Nuessler V,Cermak J,Solbu G,Willemze R,de Witte T,Amadori S
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference18 articles.
1. Greenberg P, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.
2. Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F . Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991; 77: 497–501.
3. De Witte T, Suciu G, Peetermans M, Fenaux P, Strijckmans P, Hayat M et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myelogenous leukemia following MDS of more than 6 months duration. Leukemia 1995; 9: 1805–1811.
4. deWitte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS (AML-MDS). Blood 2001; 98: 2326–2331.
5. Visani G, Malagola M, Piccaluga PP, Isidori A . Low dose Ara-C for myelodysplastic syndromes: is it still a current therapy? Leuk Lymphoma 2004; 45: 1531–1538.
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献